

DISCLAIMER



This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the section "Risk Factors" in DANONE's Annual Report (which is available on www.danone.com). DANONE undertakes no obligation to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy, Danone shares.

AGENDA



FULL YEAR 2013 RESULTS — PIERRE-ANDRÉ TERISSE, CHIEF FINANCIAL OFFICER

GROWING A STRONGER DANONE - FRANCK RIBOUD, CHIEF EXECUTIVE OFFICER

QUESTIONS & ANSWERS



KEY FIGURES – FY 2013




Sales	€ 21,298 mln	+4.8% like-for-like ⁽¹⁾ +2.1% reported
Trading operating income	€ 2,809 mln	-1.1% like-for-like ⁽¹⁾ -5.0% reported
Trading operating margin	13.19%	-81 bps like-for-like ⁽¹⁾ -99 bps reported
Underlying net income	€ 1,636 mln	-4.5% like-for-like ^{(1) (2)} -10.0% reported
Underlying EPS (fully diluted)	€ 2.78	-2.2% like-for-like ⁽¹⁾ -7.9% reported
Free cash-flow excluding exceptional items ⁽³⁾	€ 1,549 mln	-25.8% reported

- (1) Like-for-like: Based on constant scope of consolidation and constant exchange rates
- (2) Excluding non-current
- (3) Free cash-flow excluding exceptional items: cash flows provided or used by operating activities less capital expenditure net of disposals and excluding acquisition costs related to business combinations and before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt its organizations in Europe

SALES BREAKDOWN BY GEOGRAPHY



2013 SALES BY GEOGRAPHY




>60% of sales in growth markets


TOP 10 CONTRIBUTORS TO 2013 SALES

#1	Russia	11%
#2	France	10%
#3	United States	8%
#4	China	7%
#5	Indonesia	6%
#6	Spain	5%
#7	Mexico	5%
#8	Argentina	5%
#9	United Kingdom	5%
#10	Brazil	4%

2013: ADAPTING EUROPE







2013: ADAPTING EUROPE (2)





ADAPTING THE OPERATING MODEL



2013: A YEAR OF HIGH VOLATILITY







2013: IMPACT FROM FONTERRA FALSE SAFETY ALERT



Importers recall tainted NZ milk powder

Updated: 2013-08-05 10:58

(Xinhua)

Comments 🖨 Print

■ Mail

Q ☐ Large Medium Small

BEIJING -- China's importers on Sunday began to recall and seal products produced by New Zealand dairy giant Fonterra due to safety concerns over its allegedly contaminated whey protein that could cause botulism.


The recall began after the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) announced a list of four domestic companies that have imported whey products that may be contaminated with clostridium botulinum.

Fonterra said Friday that some of its whey protein produced in May 2012 was found to be contaminated with the toxic bacteria.

The four importers are China's biggest food and beverage firms Hangzhou Wahaha Health Food Co Ltd, Hangzhou Wahaha Import & Export Co Ltd, Shanghai Tangjiu (Group) Co Ltd and Shanghai-based Dumex Baby Food Co Ltd, according to AQSIQ.

Baby formula maker Dumex said it is sealing imported Fonterra products and recalling two of its branded formula products that were made with the whey protein.

Dumex has produced 726.55 tons materials and 420.19 tons have all authorities said.





SIGNIFICANT IMPACT ON 2013 GROUP RESULTS


Sales €370 mln

Cost impact €306 mln incl €201 mln one off

Cash impact €291 mln

2013: WALKING THE TALK ON KEY BATTLES







FY 2013 RESULTS VS. GUIDANCE




	2013 objectives announced FY 2012	2013 objectives adjusted Q3 2013	FY 2013
Sales growth ⁽¹⁾	At least 5%	4.5% to 5%	4.8%
Trading operating margin ⁽¹⁾	-30bps to -50bps	-80bps	13.19% -81bps
Free cash-flow excluding exceptional items ⁽²⁾	Around €2 bn	€1.5 bn to €1.6 bn	€1,549 mln

⁽¹⁾ Like-for-like: Based on constant scope of consolidation and constant exchange rates

⁽²⁾ Free cash-flow excluding exceptional items: cash flows provided or used by operating activities less capital expenditure net of disposals and excluding acquisition costs related to business combinations and before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt its organizations in Europe


FY 2013 - SALES GROWTH ANALYSIS





Q4 2013 - SALES GROWTH ANALYSIS






TOTAL GROUP: A RESILIENT GROWTH IN A TOUGH ENVIRONMENT

0.5%

Q4 13



LIKE-FOR-LIKE SALES GROWTH PER QUARTER




Q1 13

Q2 13

Q3 13

LIKE-FOR-LIKE SALES GROWTH



Solid and well-balanced growth across the board

Q4 12

Impacted by Fonterra false alert in H2


Q3 12

Q1 12

Q2 12

GEOGRAPHICAL DYNAMICS: Like-for-like sales growth









FRESH DAIRY PRODUCTS – Confirmed recovery



LIKE-FOR-LIKE SALES GROWTH PER QUARTER

LIKE-FOR-LIKE SALES GROWTH





- Europe still negative but improving
- CIS & Noram and Latam growing double digit
- * Resilient volumes in a context of price increases

FRESH DAIRY PRODUCTS – Selected innovations Q4
















WATERS – Strong and sustained topline growth







LIKE-FOR-LIKE SALES GROWTH

- Balanced growth equation
- Asia & aquadrinks keep outperforming
- * Europe stable with positive volume/value growth in some major countries
- Confirmed success in new geographies like Brazil

WATERS – Selected innovations Q4










EARLY LIFE NUTRITION – A year of two halves






- Significant impact of the Fonterra false alert in H2
- Strong performance in all other regions excluding Dumex and Karicare

EARLY LIFE NUTRITION – Zoom on Asian performance







- Inventory management
- New communication campaign










 Adjusting the organization and cost base

KEY INITIATIVES TO RECOVER













MEDICAL NUTRITION – Solid growth



LIKE-FOR-LIKE SALES GROWTH PER QUARTER

LIKE-FOR-LIKE SALES GROWTH





- * Europe resilient despite continued pressure on reimbursement policies
- Confirmed strong dynamics outside Europe

MEDICAL NUTRITION – Selected innovations Q4









TRADING OPERATING INCOME AND MARGIN




€ mIn	FY 2012	FY 2013
Trading operating income	2,958	2,809
Other operating items	(211)	(681) [*]
Operating income	2,747	2,128
Trading operating margin	14.18%	13.19%

^{*} Other operating items mainly include costs related to the European plan for savings and adaptation and to the Fonterra false alert


FY 2013 - MARGIN BRIDGE DEVELOPMENT






SHIFTING THE INVESTMENT MODEL









(i) 0:00 / 1:17



TRADING OPERATING MARGIN by business lines & geographical areas



€ mln	FY 2012	FY 2013	Like-for-like change
Fresh Dairy Products	12.11%	10.35%	(160) bps
Waters	13.23%	13.04%	+10 bps
Early Life Nutrition	19.51%	19.62%	+21 bps
Medical Nutrition	17.95%	18.16%	(4) bps
Europe	15.66%	14.42%	(121) bps
CIS+Noram	10.21%	9.56%	(24) bps
ALMA	14.81%	14.03%	(58) bps
Total	14.18%	13.19%	(81) bps


FROM OPERATING INCOME TO EPS



€ mIn	FY 2012 underlying	FY 2013 underlying	Non-current items	FY 2013
Trading operating income	2,958	2,809		2,809
Other operating items	-	-	(681)	(681)
Operating income	2,958	2,809	(681)	2,128
Total financial expenses	(300)	(311)	48	(263)
Income tax	(735)	(750)	146	(604)
Net income of affiliates	59	50	239	289
Net income	1,982	1,798	(248)	1,550
Non-controlling interests	164	162	(34)	128
Net income - Group share	1,818	1,636	(214)	1,422
			7	
Fully diluted number of share mln	603	588		
Fully diluted underlying EPS €	€ 3.01	€ 2.78		

ANALYSIS OF UNDERLYING FULLY DILUTED EPS GROWTH FY 2013






CASH BRIDGE




€ mIn




CASH DRIVERS




FREE CASH-FLOW EUROPEAN PLAN FOR SAVINGS AND ADAPTATION (€ MLN)



WORKING CAPITAL (€ MLN)




CAPITAL EXPENDITURES (€ MLN)




FCF TO NET DEBT CHANGE





SYNTHETIC BALANCE SHEET






- (1) Excluding assets included in net debt
- (2) Net of cash, cash equivalents, marketable securities, other short term investments and financial instrument assets

PROPOSED DIVIDEND TO THE NEXT AGM



DIVIDEND PROPOSED TO THE NEXT AGM ON APRIL 29TH, 2014:


- ✓ £1,45 PER SHARE
- ✓ PAYMENT IN CASH OR IN SHARES AT SHAREHOLDERS' OPTION








2014 KEY PRIORITIES











2014 GUIDANCE



	2014 objectives
Sales growth ⁽¹⁾	4.5% to 5.5%
Trading operating margin ⁽¹⁾	Stable ± 20 bps
Free cash-flow excluding exceptional items ⁽²⁾	around €1.5 bn

With no impact in 2013:


⁽¹⁾ Like-for-like: Based on constant scope of consolidation, constant exchange rates and accounting principles

⁽²⁾ Free cash-flow excluding exceptional items: cash flows provided or used by operating activities less capital expenditure net of disposals, excluding acquisition costs related to business combinations and paid subsequently to acquisition date and before cash-flows related to initiatives that may be taken by the Group to deploy the plan to generate savings and adapt its organizations in Europe

40

2014: UNBALANCED COMPARISON BASE





- Challenging H1 comparison
- * Topline and margin strongly debalanced



BRING DANONE BACK ON THE AGENDA OF A








2014 AND ONWARDS: TO GROW AND BALANCE THE MODEL






2013 MARGIN* BREAKDOWN AND LFL GROWTH



COMPLETE EUROPE TRANSFORMATION









>5k tons



















EUROPE DAIRY : DANONINO RELAUNCH EXAMPLE IN SPAIN



NEW STRATEGY BUILD A MULTI-CATEGORY BRAND PLATFORM WITH ADAPTED PRODUCTS FOR SMALL KIDS

New Positioning (Relevance)




New price points (Competitiveness)



Innovation (Uniqueness)





positive growth worldwide



EUROPE: PUSH FOR CONTINUOUS IMPROVEMENT AND TRANSFORM THE MODEL







INNOVATIONS














LEVERAGING THE UNITED STATES














KEEP BUILDING A STRONGER CIS












FRESH DAIRY PRODUCTS: A GROWING CATEGORY





IN-STORE SIGNAGE TO DEMONSTRATE HOW YOGURT CAN ADDRESS NEEDSTATES




EDUCATION AND AWARENESS






SHELF SEGMENTATION BASED ON OCCASIONS/BENEFITS



WATERS: A STRONG PILLAR









BRINGING AQUADRINKS TO CONSUMERS





SALES OF AQUADRINKS WITHIN WATER DIVISION: ≈30%

2013 GROWTH > 20%

DIFFERENTIATED DIGITAL PRESENCE



YouTube acceleration Levité saga Reading > 500,000



New Year Mizone buzz Retweet: 13,000 in 1st week



Mizone Twitter activation Reading: 3.5 Mln



Fool's Day



TAILOR-MADE TO LOCAL NEEDS AND HABITS









CONSISTENT ACTIVATION ACROSS TOUCH-POINTS









AFRICA: LEVERAGE STRONG POSITIONS









AFRICA: DESIGN NEW FRONTEERS EXAMPLE OF FAN MILK





The market leader brand in frozen dairy products and juices in West Africa

A unique and iconic street vending system with more than 31,000 independent vendors









MANY INITIATIVES TO SUPPORT THE MODEL






SOURCING: ENSURE SUSTAINABILITY AND HIGHEST QUALITY STANDARDS



SECURING LONG-TERM MILK

Build relationship with Russian firm Damate to construct new Dairy farms















DANONE: A UNIQUE MODEL FOR DOING BUSINESS






GOVERNANCE



Appointment of two new Board members (both independent) proposed to the AGM







TAX RATE DEVELOPMENT




€ mIn	FY 2012	FY 2013
Total income tax (reported)	(712)	(604)
Reported tax rate	29.1%	32.4%
Non-current income tax ⁽¹⁾	23	146
Current income tax	(735)	(750)
Underlying tax rate	27.6%	30.0%

(1) Tax related to non-current items

SHARE PRICE & SHAREHOLDING




DANONE SHARE PRICE EVOLUTION




DANONE 2013 STOCK PERFORMANCE



SHAREHOLDING BY INVESTOR (1)



INSTITUTIONAL SHAREHOLDING BY GEOGRAPHY (1)



ADR PROGRAM



DRs Outstanding as a % of Total Shares Outstanding



* Ticker: DANOY

• **CUSIP Number**: 23636T100

* Exchange: OTC QX (www.otcqx.com/qx/market/quote?symbol=DANOY)

* Ratio (ADR: ord): 5:1

* Depositary Bank: J.P. Morgan

* ADR Depositary Bank contact: Jim Reeves +1 212 552 8928 / DRX_depo@jpmorgan.com

OTEQX

IMPACT OF CURRENCIES AND SCOPE - Q4 2013



	Fresh Dairy Products	Waters	Early Life Nutrition	Medical Nutrition	Total
Reported sales growth	(0.2)%	(1.0)%	(13.4)%	+2.3%	(3.0)%
Currency	(8.0)%	(10.8)%	(8.0)%	(4.5)%	(8.2)%
Scope of consolidation	+2.9%	+1.7%	+1.5%	+0.4%	+2.3%
Like-for-like sales growth	+4.9%	+8.1%	(6.9)%	+6.4%	+2.9%

IMPACT OF CURRENCIES AND SCOPE – FY 2013



	Fresh Dairy Products	Waters	Early Life Nutrition	Medical Nutrition	Total
Reported sales growth	+1.0%	+7.0%	+0.2%	+4.2%	+2.1%
Currency	(5.4)%	(5.3)%	(4.5)%	(3.2)%	(5.1)%
Scope of consolidation	+3.2%	+1.1%	+1.1%	+1.6%	+2.4%
Like-for-like sales growth	+3.2%	+11.2%	+3.6%	+5.8%	+4.8%

Q4 2013 SALES BY BUSINESS & GEOGRAPHICAL AREA



€ mIn	Q4 2012	Q4 2013	Like-for-like sales growth
Fresh Dairy Products	2,859	2,854	+4.9%
Waters	832	823	+8.1%
Early Life Nutrition	1,105	956	(6.9)%
Medical Nutrition	340	348	+6.4%
Europe	1,992	1,969	(0.4)%
CIS+Noram	1,109	1,170	+10.2%
ALMA	2,035	1,842	+2.2%
Total	5,136	4,981	+2.9%

FY 2013 SALES BY BUSINESS & GEOGRAPHICAL AREA



€ mIn	FY 2012	FY 2013	Like-for-like sales growth
Fresh Dairy Products	11,675	11,790	+3.2%
Waters	3,649	3,903	+11.2%
Early Life Nutrition	4,257	4,263	+3.6%
Medical Nutrition	1,288	1,342	+5.8%
Europe	8,431	8,197	(2.4)%
CIS+Noram	4,426	4,713	+10.0%
ALMA	8,012	8,388	+10.0%
Total	20,869	21,298	+4.8%

Q4 2013 LIKE-FOR-LIKE SALES GROWTH BREAKDOWN VOLUME/VALUE



Like-for-like	Volume	Price/mix	Total
Fresh Dairy Products	+0.8%	+4.1%	+4.9%
Waters	+6.0%	+2.1%	+8.1%
Early Life Nutrition	(5.9)%	(1.0)%	(6.9)%
Medical Nutrition	+4.8%	+1.6%	+6.4%
Europe	(0.6)%	+0.2%	(0.4)%
CIS+Noram	+2.9%	+7.3%	+10.2%
ALMA	(0.8)%	+3.0%	+2.2%
Total	+0.5%	+2.4%	+2.9%

FY 2013 LIKE-FOR-LIKE SALES GROWTH BREAKDOWN VOLUME/VALUE



Like-for-like	Volume	Price/mix	Total
Fresh Dairy Products	+1.7%	+1.5%	+3.2%
Waters	+6.8%	+4.4%	+11.2%
Early Life Nutrition	(0.7)%	+4.3%	+3.6%
Medical Nutrition	+5.5%	+0.3%	+5.8%
Europe	(1.6)%	(0.8)%	(2.4)%
CIS+Noram	+5.3%	+4.7%	+10.0%
ALMA	+3.6%	+6.4%	+10.0%
Total	+2.3%	+2.5%	+4.8%

CASH FLOW STATEMENT



€mIn	FY 2012	FY 2013
Operating income	2,958	2,809
Financial income	(300)	(311)
Income tax	(735)	(750)
Non-current income	(190)	(493)
Depreciation and amortization	670	710
Net change in provisions	61	76
Dividend received from equity accounted affiliates	35	27
Other cash items	(26)	(35)
Other non-cash items	52	93
Cash flow provided by operating activities, excluding changes in net working capital	2,525	2,126

CASH FLOW STATEMENT



€ mIn	FY 2012	FY 2013
Cash flow provided by operating activities, excluding changes in net working capital	2,525	2,126
Change in working capital	333	224
Cash flow from operations	2,858	2,356
Capital expenditure	(976)	(1,039)
Proceeds from the sale of industrial assets	193	79
Business acquisitions and other investments, net of cash and cash equivalent acquired	(291)	(1,246)
Proceeds from the sale of businesses	4	69
Change in long-term loans and other long-term assets	(1)	(19)
Cash flow used in investing activities and disposals	(1,071)	(2,156)

CASH FLOW STATEMENT



€ mIn	FY 2012	FY 2013
Increase in capital and additional paid-in capital	35	37
Purchases of treasury stock (net of disposal)	(701)	(793)
Dividends paid to danone shareholders	(835)	(848)
Transactions with non controlling interests*	(339)	(213)
Settlement of debt hedge financial instruments	(70)	54
Current and non-current financings issued or raised during the period	1,585	2,933
Current and non-current financings repaid during the period	(328)	(337)
Change in cash equivalents	(831)	(1,176)
Cash flow used in financing activities	(1,484)	(343)
Exchange rate differences	(61)	(157)
Increase (decrease) in cash	242	(306)
* including dividends		

^{*} including dividends

CHANGES IN EXCHANGE RATES 28.0% OF SALES DENOMINATED IN €



% total	FY	13
sal	es	

FY 13 vs FY 12 (avg) Q4 13 vs Q4 12 (avg)

Russian ruble
US dollar
Chinese yuan
Indonesian rupiah
Mexican peso
Argentine peso
British pound
Brazilian real
Polish zloty
Moroccan Dirham

10.5%
9.2%
5.9%
5.6%
5.4%
4.9%
4.8%
4.4%
2.6%
2.4%

-5.7%
-3.2%
-0.7%
-13.0%
-0.3%
-19.6%
-4.5%
-12.5%
-0.3%
-0.6%

-9.0%
-4.7%
-2.2%
-20.6%
-5.3%
-24.5%
-3.9%
-13.8%
-1.7%
-0.9%

